BridgeMD
New treatment option for RCC, Renal Cell Cancer
Official title Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial
ClinicalTrials.gov ID: NCT07190638
What this study is testing
- What it's testing
- Renal function preservation is a growing concern in the surgical management of kidney tumors, particularly with the rise in chronic kidney disease worldwide. Recent surgical innovations have focused on modifying renorrhaphy techniques to minimize renal damage.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of renal mass confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)
- Indication for partial nephrectomy
- Written informed consent
- Expected survival of at least 6 months
- Eastern Cooperative Oncology Group (ECOG) score performance status ≤ 1
You likely can't join if
- Solitary kidney
- Multiple or bilateral renal masses if more than one mass is operated on simultaneously or within less than 4 months
- Hepatic or renal toxicity grade ≥ 2 with glomerular filtration rate (GFR) \< 30 according to Common Terminology Criteria for Adverse Events (CTCAE v4)
- Bleeding diathesis
- Inability to maintain anticoagulation for surgery
- Participation in another experimental trial simultaneously or within 30 days prior to enrollment
See the full eligibility criteria
- Diagnosis of renal mass confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)
- Indication for partial nephrectomy
- Written informed consent
- Expected survival of at least 6 months
- Eastern Cooperative Oncology Group (ECOG) score performance status ≤ 1
- Negative serum or urine pregnancy test within 24 hours before surgery for women of childbearing potential
- Recovery from any prior therapy-related toxicity to grade 1 or better
- If a biopsy has been performed, pathology consistent with renal cell carcinoma (RCC)
- Solitary kidney
- Multiple or bilateral renal masses if more than one mass is operated on simultaneously or within less than 4 months
- Hepatic or renal toxicity grade ≥ 2 with glomerular filtration rate (GFR) \< 30 according to Common Terminology Criteria for Adverse Events (CTCAE v4)
- Bleeding diathesis
- Inability to maintain anticoagulation for surgery
- Participation in another experimental trial simultaneously or within 30 days prior to enrollment
- Significant acute or chronic medical, neurological, or psychiatric condition that could compromise safety, limit study completion, or impair study objectives in the opinion of the Principal Investigator
The study team makes the final eligibility decision.
Where it's taking place
- Salvador, Estado de Bahia, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Salvador, Estado de Bahia, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.